Cyclo Therapeutics (CYTH.US) was first covered by Ascendiant Capital, giving it a buy rating, with a target price of $2.60.
Cyclo Therapeutics(CYTH.US)获Ascendiant Capital首次覆盖，给予买入评级, 目标价2.60美元。
Cyclo Therapeutics (CYTH.US) was first covered by Ascendiant Capital, giving it a buy rating, with a target price of $2.60.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.